Literature DB >> 26259399

Splenomegaly in Sarcoidosis: Frequency, Treatment, Prognosis and Long-term Follow-up.

Zora Pavlović-Popović, Bojan Zarić, Zdravko Kosjerina, Dragana Petrović.   

Abstract

INTRODUCTION: The splenic involvement is common in sarcoidosis, but its real frequency is still obscure depending doubtless on the method of splenomegaly detection. Splenomegaly may be accompanied with pain or anemia, leucopenia and thrombocytopenia.
OBJECTIVE: The aim of this study was to investigate the frequency of splenomegaly related to clinical characteristics of sarcoidosis and to solve the dilemma--whether to introduce medicaments, and when to perform splenectomy.
METHODS: The method of the study is a retrospective and prospective analysis of the patients'material.
RESULTS: The study included 540 patients with sarcoidosis in a 20-year period. Of them, 26% had splenomegaly detected by computerized tomography screening. Splenomegaly was more frequently registered in the patients with a longer history of sarcoidosis (38%), as compared to those with a shorter history of the disease (23%) (p < 0.05). Splenomegaly was more frequently registered in the patients with other extrapulmonary lesions detected (33%) than in those who had no extrapulmonary manifestations of sarcoidosis (17%) (p < 0.01). Indications, possible benefits and complications of splenectomy were analysed in 11 sarcoidosis patients undergoing this intervention for various reasons, of which the follow-up period ranged from one to 20 years.
CONCLUSION: Splenomegaly was more frequent in chronic cases or in the patients with established sarcoid lesions of other extrapulmonary organs.The primary treatment of uncomplicated symptomatic splenic sarcoidosis includes medicamentous therapy. Occasionally, splenectomy is required. Prognostically, splenomegaly indicates an unfavorable course of the disease.

Entities:  

Mesh:

Year:  2015        PMID: 26259399     DOI: 10.2298/sarh1506279p

Source DB:  PubMed          Journal:  Srp Arh Celok Lek        ISSN: 0370-8179            Impact factor:   0.207


  6 in total

1.  Autoantibody profile in sarcoidosis, analysis from the GRADS sarcoidosis cohort.

Authors:  Basheer Khassawneh; Chengsong Zhu; Briana Barkes; Brian Vestal; Sarah Shrock; May Gillespie; Karin Pacheco; Kevin D Deane; Lisa A Maier; Quan-Zhen Li; Nabeel Hamzeh
Journal:  PLoS One       Date:  2022-10-20       Impact factor: 3.752

2.  Bone marrow involvement in sarcoidosis: an elusive extrapulmonary manifestation.

Authors:  J Isaac Peña-Garcia; Sana Shaikh; Bhishma Barakoti; Christos Papageorgiou; Alexandre Lacasse
Journal:  J Community Hosp Intern Med Perspect       Date:  2019-04-12

3.  Sarcoidosis presenting as massive splenomegaly and severe epistaxis, case report.

Authors:  Austen Stoelting; Shawn Esperti; Nino Balanchivadze; Valentino Piacentino; Andrew Mangano
Journal:  Ann Med Surg (Lond)       Date:  2020-04-08

4.  "The Great Mimicker": An Unusual Etiology of Cytopenia, Diffuse Lymphadenopathy, and Massive Splenomegaly.

Authors:  Mazen Zaarour; Chanudi Weerasinghe; Elias Moussaly; Shafinaz Hussein; Jean-Paul Atallah
Journal:  Case Rep Med       Date:  2015-10-22

5.  Clinical characteristics and organ system involvement in sarcoidosis: comparison of the University of Minnesota Cohort with other cohorts.

Authors:  Hok Sreng Te; David M Perlman; Chetan Shenoy; Daniel J Steinberger; Rebecca J Cogswell; Henri Roukoz; Erik J Peterson; Lin Zhang; Tadashi L Allen; Maneesh Bhargava
Journal:  BMC Pulm Med       Date:  2020-06-01       Impact factor: 3.317

6.  Atypical Sarcoidosis Diagnosed by Massive Splenomegaly.

Authors:  Satomi Saito; Kazuhisa Kodama; Tomomi Kogiso; Yuki Yamanashi; Makiko Taniai; Shunichi Ariizumi; Masakazu Yamamoto; Katsutoshi Tokushige
Journal:  Intern Med       Date:  2019-10-31       Impact factor: 1.271

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.